AGENTIX CORP.

AGTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $0 $1.2K $1.2K
Cost of Revenue $0 $561 $561
Gross Profit $0 $679 $679
Gross Margin 54.8% 54.8%
Operating Expenses
Research & Development $125.1K $181.0K $175.3K $711.5K $279.9K $365.1K
SG&A Expense $68.1K $69.9K $346.5K $140.0K $165.4K $66.4K $4.0K
Operating Income $-445.2K $-513.3K $-744.8K $-1.4M $-2.6M $-1.3M $-121.3K
Operating Margin -211,825.1% -108,092.9%
Interest Expense $80.1K $42.7K $21.0K $1.6K $11.3K
Pretax Income $-485.6K $-567.0K $-585.2K $-1.4M $-1.3M $-132.7K
Income Tax Expense $0 $0 $0 $0 $0 $0
Net Income $-485.6K $-567.0K $-585.2K $-1.4M $-2.6M $-1.3M $-132.7K
Net Margin -211,825.1% -108,092.5%
EPS (Basic) $-0.04 $-6.45
EPS (Diluted) $-0.01 $-0.01 $-0.01 $-0.04 $-6.45
Shares Outstanding (Basic) 40.1M 38.9M 34.9M 34.5M 25.3K
Shares Outstanding (Diluted) 40.1M 40.1M 40.1M 40.1M 38.9M 34.9M 34.5M 25.3K
Dividends Per Share
← Newer Page 1 of 2 Older →